Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats

Linagliptin potentiates the effect of l -dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1

(2018) Ahmed M. Kabel et al.   PHYSIOLOGY & BEHAVIOR

Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator

(2017) RobertL Haining et al.   Neural Regeneration Research

Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

(2017) Ghada A. Badawi et al.   INFLAMMOPHARMACOLOGY

Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4

(2016) M. Larsson et al.   BIOSCIENCE REPORTS

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

(2016) Dilan Athauda et al.   DRUG DISCOVERY TODAY

Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action

(2016) Maurício dos-Santos-Pereira et al.   NEUROBIOLOGY OF DISEASE

Ibuprofen or piroxicam protects nigral neurons and delays the development of l -dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis

(2016) Asmaa M. Teema et al.   NEUROPHARMACOLOGY

The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological findings

(2015) Christof von Wrangel et al.   BEHAVIOURAL BRAIN RESEARCH

Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways

(2015) Rania M. Abdelsalam et al.   JOURNAL OF NEUROCHEMISTRY

The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases

(2015) Burak Yulug et al.   Medicinal Chemistry

Saxagliptin: A novel antiparkinsonian approach

(2015) Noha N. Nassar et al.   NEUROPHARMACOLOGY

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

(2015) Simon C. Cork et al.   Molecular Metabolism

Neuroinflammation in Parkinson’s disease and its potential as therapeutic target

(2015) Qinqin Wang et al.   Translational Neurodegeneration

Pharmacological Treatment of Parkinson Disease

(2014) Barbara S. Connolly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats

(2014) Ajaykumar N. Sharma et al.   METABOLIC BRAIN DISEASE

Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice

(2014) Sawsan A. Zaitone et al.   Pharmacological Reports

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

(2014) Kelly M. Lohr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Parkinson disease: from pathology to molecular disease mechanisms

(2013) David T. Dexter et al.   FREE RADICAL BIOLOGY AND MEDICINE

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus

(2013) Tonya N. Taylor et al.   NEUROPHARMACOLOGY

Neuromelanin of the Human Substantia Nigra: An Update

(2013) Fabio A. Zucca et al.   NEUROTOXICITY RESEARCH

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model

(2013) Vadivel Parthsarathy et al.   PLoS One

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats

(2012) DinaM Abo-Elmatty et al.   INDIAN JOURNAL OF PHARMACOLOGY

GLP-1 secretion by microglial cells and decreased CNS expression in obesity

(2012) Camilla Kappe et al.   Journal of Neuroinflammation

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat

(2012) Amjad Abuirmeileh et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease

(2012) J. Guridi et al.   Parkinsons Disease

Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels

(2011) Simone Bido et al.   JOURNAL OF NEUROCHEMISTRY

Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia

(2011) Choong Hyun Lee et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity

(2011) Amany A. Abdin et al.   NEUROSCIENCE RESEARCH

Acetyl-l-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy

(2011) Sawsan A. Zaitone et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat

(2010) Emma L. Lane et al.   BEHAVIOURAL BRAIN RESEARCH

Dopamine quinones interact with α-synuclein to form unstructured adducts

(2010) Marco Bisaglia et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

(2010) Alexander Harkavyi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Levodopa-related wearing-off in Parkinson's disease: identification and management

(2009) Rajesh Pahwa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

(2009) Sehee Kim et al.   JOURNAL OF ENDOCRINOLOGY

A highly reproducible rotenone model of Parkinson's disease

(2009) Jason R. Cannon et al.   NEUROBIOLOGY OF DISEASE

Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease

(2009) Wei Zhang et al.   NEUROTOXICITY RESEARCH

Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease

(2008) Luigi Zecca et al.   ACTA NEUROPATHOLOGICA

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Epidemiology of Parkinson’s disease

(2008) Guido Alves et al.   JOURNAL OF NEUROLOGY

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

Progress in Parkinson's disease—Where do we stand?

(2008) André Toulouse et al.   PROGRESS IN NEUROBIOLOGY

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH